80 related articles for article (PubMed ID: 4082790)
1. [Initial results of the clinical use of the immunostimulant bestatin (3-amino-2-hydroxy-4-phenylbutyryl leucine) in patients with chronic polyarthritis].
Meske S; Vogt P; Maly FE; Seitz M; Müller W
Z Rheumatol; 1985; 44(5):231-6. PubMed ID: 4082790
[TBL] [Abstract][Full Text] [Related]
2. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
[TBL] [Abstract][Full Text] [Related]
4. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
Blomgren H; Edsmyr F; Esposti PL; Näslund I
Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
[TBL] [Abstract][Full Text] [Related]
5. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
6. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
7. [Immunomodulating basic therapy of rheumatoid arthritis using ciamexone].
Baerwald C; Goebel KM; Krause A; Heymanns J
Schweiz Med Wochenschr; 1989 Dec; 119(49):1769-71. PubMed ID: 2533393
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].
Kurita S; Ota K; Yamada K; Massaoka T; Uzuka Y; Ogawa N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2742-50. PubMed ID: 6508324
[TBL] [Abstract][Full Text] [Related]
9. Bestatin therapy of patients with atopic dermatitis.
Thestrup-Pedersen K; Cramers M; Kongsholm H; Zachariae H
Acta Derm Venereol; 1983; 63(6):549-52. PubMed ID: 6198850
[TBL] [Abstract][Full Text] [Related]
10. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
Blomgren H; Strender LE; Edsmyr F
Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
[TBL] [Abstract][Full Text] [Related]
11. [Combined immunomodulating therapy in rheumatoid arthritis].
Oliunin IuA; Balabanova RM
Ter Arkh; 1996; 68(5):13-6. PubMed ID: 9082588
[TBL] [Abstract][Full Text] [Related]
12. Influence of Bestatin, a new immunomodulator, on various functions of human monocytes.
Jarstrand C; Blomgren H
J Clin Lab Immunol; 1982 Dec; 9(3):193-8. PubMed ID: 7166751
[TBL] [Abstract][Full Text] [Related]
13. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
14. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Smeets TJ; Dayer JM; Kraan MC; Versendaal J; Chicheportiche R; Breedveld FC; Tak PP
Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
[TBL] [Abstract][Full Text] [Related]
15. [Cellular immunity in chronic polyarthritis: the effect of basic therapy on T-lymphocyte subpopulations].
Rosenthal M; Sendelova S
Schweiz Med Wochenschr; 1983 Mar; 113(11):394-8. PubMed ID: 6221406
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
[TBL] [Abstract][Full Text] [Related]
17. [Basic therapy of rheumatoid arthritis with thiopronine. Preliminary results].
Fossaluzza V; Di Benedetto P; Pinat F; Pasqualini M; Massarutto C; Pirrone S; Rossi P; Tosato F; Lucas C; Padovani R
Minerva Med; 1983 Mar; 74(13):723-6. PubMed ID: 6339997
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
[TBL] [Abstract][Full Text] [Related]
19. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
20. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
